WAT vs. ILMN, BIO, AVTR, RVTY, BIO.B, ALNY, GMAB, COO, HOLX, and PHG
Should you be buying Waters stock or one of its competitors? The main competitors of Waters include Illumina (ILMN), Bio-Rad Laboratories (BIO), Avantor (AVTR), Revvity (RVTY), Bio-Rad Laboratories (BIO.B), Alnylam Pharmaceuticals (ALNY), Genmab A/S (GMAB), Cooper Companies (COO), Hologic (HOLX), and Koninklijke Philips (PHG). These companies are all part of the "medical" sector.
Waters (NYSE:WAT) and Illumina (NASDAQ:ILMN) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, community ranking, institutional ownership, dividends, profitability and earnings.
Waters has a net margin of 21.72% compared to Illumina's net margin of -25.78%. Waters' return on equity of 81.30% beat Illumina's return on equity.
Waters has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500. Comparatively, Illumina has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500.
Waters currently has a consensus target price of $298.67, suggesting a potential downside of 4.06%. Illumina has a consensus target price of $167.70, suggesting a potential upside of 37.14%. Given Illumina's stronger consensus rating and higher possible upside, analysts clearly believe Illumina is more favorable than Waters.
Waters has higher earnings, but lower revenue than Illumina. Illumina is trading at a lower price-to-earnings ratio than Waters, indicating that it is currently the more affordable of the two stocks.
In the previous week, Waters had 31 more articles in the media than Illumina. MarketBeat recorded 36 mentions for Waters and 5 mentions for Illumina. Illumina's average media sentiment score of 0.93 beat Waters' score of 0.30 indicating that Illumina is being referred to more favorably in the news media.
94.0% of Waters shares are held by institutional investors. Comparatively, 89.4% of Illumina shares are held by institutional investors. 0.8% of Waters shares are held by company insiders. Comparatively, 0.2% of Illumina shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Illumina received 647 more outperform votes than Waters when rated by MarketBeat users. Likewise, 65.73% of users gave Illumina an outperform vote while only 54.58% of users gave Waters an outperform vote.
Summary
Waters beats Illumina on 10 of the 18 factors compared between the two stocks.
Get Waters News Delivered to You Automatically
Sign up to receive the latest news and ratings for WAT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding WAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
